Pulmonary Hypertension

PAH Incidence in Systemic Sclerosis: Does Algorithm Use Affect Reported Incidence?

PAH Incidence in Systemic Sclerosis: Does Algorithm Use Affect Reported Incidence?

By

Use of the DETECT algorithm did not change incidence of PAH, but led to an increased frequency of cases of borderline pulmonary hypertension.

Predicting Mortality in Systemic Sclerosis-PAH With CT Signs of Veno-Occlusive Disease

Predicting Mortality in Systemic Sclerosis-PAH With CT Signs of Veno-Occlusive Disease

By

A blinded analysis sought to determine whether CT signs of pulmonary veno-occlusive disease are common and predictive of mortality in patients with systemic sclerosis and pulmonary arterial hypertension.

Dual Therapy Improves Treatment Response in Connective Tissue Disease-Associated Pulmonary Hypertension

Dual Therapy Improves Treatment Response in Connective Tissue Disease-Associated Pulmonary Hypertension

By

Post hoc study subgroup analysis shows combination ambrisentan plus tadalafil therapy improves treatment response in patients with connective tissue disease-associated pulmonary arterial hypertension.

Should the Walk Test Be Used as a Surrogate Marker for CV Hemodynamics in SSc-PAH?

Should the Walk Test Be Used as a Surrogate Marker for CV Hemodynamics in SSc-PAH?

By

The 6MWD may not accurately serve as a surrogate indicator of treatment outcomes, and that changes in cardiac hemodynamics in response to treatment in patients with SSc-PAH may not be reliably gauged from the 6MWD.

RHC Parameters Prognostic of Survival in CTD-ILD

RHC Parameters Prognostic of Survival in CTD-ILD

By

Mild elevations in MPAP were commonly found in newly diagnosed CTD-ILD, regardless of the background CTD, in this cohort of patients.

Independent Risk Factors for SLE-Associated PAH Identified

Independent Risk Factors for SLE-Associated PAH Identified

By

This study identified variables that were associated with pulmonary hypertension in a group of patients with Systemic Lupus Erythematosus (SLE).

Endothelin Receptor Antagonist Therapy Less Effective for SSc-related PH

Endothelin Receptor Antagonist Therapy Less Effective for SSc-related PH

By

Intial therapy with an endothelin receptor antagonist resulted in increased clinical worsening compared to initial treatment with PDE5 inhibitor.

Anti-U1 RNP Positivity Associated With Increased Survival in CTD-Associated PAH

Anti-U1 RNP Positivity Associated With Increased Survival in CTD-Associated PAH

By

Hemodynamic data and survival were compared in a subgroup of patients with pulmonary arterial hypertension in the setting of connective tissue disease.

Case Study and Clinical Highlight:  Diagnosis of Pulmonary Involvement in Systemic Sclerosis

Case Study and Clinical Highlight: Diagnosis of Pulmonary Involvement in Systemic Sclerosis

By

Engage in this case study to test your diagnostic ability to differentiate pulmonary hypertension in the setting of systemic sclerosis.

Sign Up for Free e-newsletters